Search

A phase II clinical trial for a phage lysin has been deemed successful! An anti-Staphylococcus aureus phage lysin, called exebacase, was just found to be both safe and effective at treating MRSA in patients. Exebacase is being developed by

IPATH has just received FDA approval to start its first clinical trial! This will be the first US trial involving intravenous (IV) phage treatment, and will be a collaboration with Ampliphi Biosciences.

Mt. Sinai Hospital in NYC is now recruiting patients for a randomized, controlled, double-blind, Phase 1/2a phage therapy trial. The goal: test the safety and efficacy of Intralytix's EcoActive phage collection on intestinal AIEC (adherent

Intralytix's phage clinical trial (treating E. coli in IBD patients) at Mt. Sinai hospital has begun! Here's a video interview with two Mt. Sinai doctors involved in the trial

Intralytix's phage clinical trial (treating E. coli in IBD patients) at Mt. Sinai hospital has begun! Here's a video interview with two Mt. Sinai doctors involved in the trial

Mt. Sinai Hospital in NYC is now recruiting patients for a randomized, controlled, double-blind, Phase 1/2a phage therapy trial. The goal: test the safety and efficacy of Intralytix's EcoActive phage collection on intestinal AIEC (adherent

IPATH has just received FDA approval to start its first clinical trial! This will be the first US trial involving intravenous (IV) phage treatment, and will be a collaboration with Ampliphi Biosciences.

Adaptive Phage Therapeutics has partnered with Yale University to manufacture and supply phages for use in Yale's upcoming clinical trials.

A phase II clinical trial for a phage lysin has been deemed successful! An anti-Staphylococcus aureus phage lysin, called exebacase, was just found to be both safe and effective at treating MRSA in patients. Exebacase is being developed by

BiomX has dosed the first cystic fibrosis patient in its Phase 2b trial of BX004 for chronic Pseudomonas aeruginosa infections. Bacteriophage.news

The Czech medicines regulator SÚKL has granted consent to begin phase II B clinical evaluation of DUOFAG®. This follows completed phase I, which confirmed the product’s safety, and ongoing phase II A examining efficacy in patients with comp